Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824170 | 0.86 | AKR1B10 (0.44) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL2847794 | 0.85 | KDM4E (0.49) | AKR1B1PTGDR2KDM4EHPGDHTT | |
| SCHEMBL3333756 | 0.84 | AKR1B1 (0.54) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL3331245 | 0.82 | KDM4E (0.46) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL1120374 | 0.80 | AKR1B1 (0.62) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL2819336 | 0.80 | KDM4E (0.70) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL2822185 | 0.79 | KDM4E (0.57) | AKR1B1AKR1B10AKR1A1KDM4EHPGD | |
| SCHEMBL2854047 | 0.78 | TDP1 (0.44) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E | |
| SCHEMBL2820567 | 0.77 | KDM4E (0.44) | AKR1B1AKR1B10AKR1A1KDM4EHPGD | |
| SCHEMBL1120582 | 0.77 | AKR1B1 (0.63) | AKR1B1AKR1B10AKR1A1PTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-2179999-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | National University Corporation University Of Toyama (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179999-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | National University Corporation University Of Toyama (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | AKR1C4, AKR1C2, AKR1C3 | AKR1B1 4/4885AKR1B10 10/4885AKR1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.